CVC talks $4B Alvogen sale with Shanghai after just 2 years of ownership

26th September 2017 Uncategorised 0

Amid a wave of pricing pressure and consolidation in the generics industry, another sale is brewing. The private equity owners of Alvogen—which include CVC Capital Partners—are weighing their options for the New Jersey drugmaker, which could be valued at about $4 billion, Bloomberg reports. And a sale of Alvogen’s U.S. business to Shanghai Pharmaceuticals Holding Co. is on the table.

More: CVC talks B Alvogen sale with Shanghai after just 2 years of ownership
Source: fierce